This switch in glucagon/GLP1 relative potency balance from 2.6 to 0.06 for Oxm and Aib2-Oxm respectively makes Aib2-Oxm a GLP-1 biased dual agonist similar to published dual agonists being pursued as type 2 diabetes therapeutics (14, 15). This evidence concerns the gene GCG and type 2 diabetes mellitus.